Otrio and Akriderm from the Akrikhin portfolio have been given awards at the 10th anniversary ceremony of the annual Russian Pharma Awards®.

These pharmaceuticals by Akrikhin were recognized in three nominations of Russian Pharma Awards® 2021 simultaneously, including:

• “Affordable cholesterol absorption inhibitor” – Otrio;
• “Topical glucocorticoids with a pronounced anti-inflammatory effect” – Akriderm;
• “Combined effect gel for musculoskeletal pain” – Bystrumgel.

According to the results of a large-scale poll among medical practitioners throughout Russia, Otrio (1^st place) and Akriderm (2^nd place) won their nominations.

Otrio is the first generic of the ezetimibe molecule in the Russian Federation. This is an original product of Akrikhin.

Today, Akriderm is the largest dermatological drug on the Russian market and the leader in the category of external glucocorticosteroids (CSs).

We are thrilled about this recognition and would like to extend our gratitude to the professional medical community for the high rating of our products. Since 1936, Akrikhin has been developing high-quality, advanced and affordable pharmaceuticals, which are trusted by both medical practitioners and many residents of Russia. We are building and value a professional dialogue with doctors, which helps the company to better understand the needs of the patients, improve its portfolio and move forward,

– commented Denis Chetverikov, President of Akrikhin, on the award outcomes.

This year Russian Pharma Awards® is celebrating its anniversary and is being held in Russia for the 10th time. The award offers 16 nominations for pharmaceuticals of various therapeutic areas, as well as separate nominations for pharmaceutical companies. The winners of the award were determined by direct voting among practitioners at Doctor at Work, the largest professional platform for doctors in Russia.

¹By the volume of sales in monetary terms for the Akriderm brand according to IQVIA retail data across all categories of dermatology (09'2021)